Logo

Genome Therapeutics Extends Alliance With Astra Research Center

Dec 18, 1998
Premium

WALTHAM, Mass.--Genome Therapeutics here and Astra Research Center, a drug discovery company recently established in Cambridge, Mass., by Swedish pharmaceutical company, Astra, have extended until at least August, 1999, their alliance to identify and develop novel antiinfectives and vaccines to treat Helicobacter pylori, the organism associated with the onset of most peptic ulcers and certain stomach cancers. Announced in September 1995, the $22 million alliance centers around the genomic sequence of H. pylori, determined by Genome Therapeutics in 1994.

Genome Therapeutics also announced it has reached a milestone in its human genomics alliance with Schering-Plough to discover new therapeutics for treating asthma. The achievement triggers a milestone payment.

Filed under

Informatics
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.